Jacobi A, Thieme S, Lehmann R, Ugarte F, Malech HL, Koch S, Thiede C, Müller K, Bornhäuser M, Ryser M, Brenner S (2010) Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp Hematol 38(3), 180-190.

Nilsson I, Bahram F, Li X, Gualandi L, Koch S, Jarvius M, Söderberg O, Anisimov A, Kholová I, Pytowski B, Baldwin M, Ylä-Herttuala S, Alitalo K, Kreuger J, Claesson-Welsh L (2010) VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J 29(8), 1377-1388.

Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, Ehninger G, Thiede C (2010) Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Ann Hematol 89(7), 653-662.

Schmidt-Arras D, Böhmer SA, Koch S, Müller JP, Blei L, Cornils H, Bauer R, Korasikha S, Thiede C, Böhmer FD (2009) Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Blood 113(15), 3568-3576.

Verstraete K, Koch S, Ertugrul S, Vandenberghe I, Aerts M, Vandriessche G, Thiede C, Savvides SN (2009) Efficient production of bioactive recombinant human Flt3 ligand in E. coli. Protein J 28(2), 57-65.

Koch S, Jacobi A, Ryser M, Ehninger G, Thiede C (2008) Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis. Cells Tissues Organs 188(1-2), 225-235.

Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107(10), 4011-4020.

Neuschäfer-Rube F, Engemaier E, Koch S, Böer U, Püschel GP (2003) Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J 371(Pt 2), 443-449.